Skip to main content
. 2022 Jun 24;54:102384. doi: 10.1016/j.redox.2022.102384

Fig. 6.

Fig. 6

MSN-NGR1-CD11b antibody nanoparticles injected intravenously promote angiogenesis. Immunofluorescence detection of the number of CD31-positive cells at the infarct site (A, B). Scale bar: 100 μm (left), 50 μm (right) and 10 μm (magnification).**P < 0.01 versus the MI group; ##P < 0.01 versus the MI + MSN-NGR1 group. MSN-NGR1-CD11b antibody nanoparticles increased the expression of VEGF and bFGF according to ELISA assay (C, D). *P < 0.05, **P < 0.01 versus the MI group; ##P < 0.01 versus the MSN-NGR1 group.